Screening for Carcinoid Heart Disease: Trends and Future Perspectives

Background Screening for carcinoid heart disease (CHD), has historically lacked consensus expert guidelines. In 2017, the North American Neuroendocrine Tumor Society (NANETS) released expert recommendations for CHD screening among NET patients to improve CHD detection. The objective of this study is to evaluate CHD screening trends and utility of screening guidelines over more than two decades at a single tertiary care center. Materials and Methods Patients with NETs referred for abdominal surgical evaluation at a single tertiary care center were included, 300 patients from 1999-2018 and 34 patients from 2021-2022. Lab values for the following NANETS-proposed criteria at any point during their treatments were recorded: NETs with liver metastasis, blood serotonin >5 times upper limit of normal (>1000 ng/mL), NT-ProBNP > 260 pg/mL and clinical features suggestive of CHD. Results 85% (285/334) of patients included in this study met one or more expert-recommended CHD screening criteria. However, 40% (132/285) of patients meeting one or more criteria received CHD screening via echocardiogram at some point following NET diagnosis. While rates of screening for patients increased from the first decade to the second decade (32% vs 40.6%), the rates were much higher after guideline publication (70%, 24/34). Furthermore, patients meeting multiple screening criteria were more likely to have evidence of structural valve disease. Conclusions Results of this study suggest that utilization of these four expert-recommended screening criteria have greatly increased rates of CHD screening via echocardiogram and could assist in improving early CHD detection, especially for patients meeting multiple criteria.